Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Recruiting now · Phase 1/Phase 2
Conditions studied: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
In brief
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
Key facts
- Study ID
- NCT06374459
- Run by
- Washington University School of Medicine
- People needed
- 152
- Starts
- 2025-01-30
- Expected to finish
- 2032-05-31
- Last updated by the study team
- 2026-04-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The University of Kansas Cancer Center — Westwood, Kansas, United States (enrolling)
- Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.